{"entity":{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","aka":[],"tldr":"Instead of shipping a patient's cells to a distant factory, hospitals would make CAR-T on site under a shared licence, cutting cost and waiting time.","summary":"Academic point-of-care CAR-T already exists: ARI-0001 (Hospital Clinic Barcelona, approved under Spain's hospital exemption at roughly a third of commercial cost), NexCAR19 in India (ImmunoACT, list price around $40,000) and several Chinese and Israeli programmes. The MHRA's 2025 framework for point-of-care and modular manufacturing allows one authorisation to cover multiple hospital sites under a central control site. The proposal is a network of 20-30 hospital GMP suites making a common CD19 (and later BCMA) product from a shared master file, with pooled release testing data and a single outcomes registry.","asOf":"2026-09-08","links":[{"label":"MHRA point of care manufacturing framework (page moved; nearest live section)","url":"https://www.gov.uk/government/news/"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia","multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cartitude-4","karmma-3","nct06413498","nct06464991","zuma-7"],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-drug-pricing"],"keyPapers":["paper-cd19-all-leukemia-j-clin-invest-2016","paper-cd19-all-leukemia-j-clin-oncol-2014","paper-cd19-all-leukemia-blood-2015"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Network-manufactured CAR-T achieves a vein-to-vein time under 14 days and a fully loaded cost per dose below $100,000 while matching the complete response rate and cytokine release syndrome profile of commercial products in the same indication.","rationale":"The cost of autologous CAR-T is dominated by logistics, single-site capital and margin, not materials. Closed automated devices (CliniMACS Prodigy, Cocoon) make hospital manufacture reproducible, and a shared master file spreads the regulatory burden that no single hospital could carry.","test":"Fund a ten-hospital pilot in one health system with a shared control site and master file; compare vein-to-vein time, manufacturing failure rate, cost and 12-month outcomes with contemporaneous commercial CAR-T recipients in the same system.","maturity":"early-clinical","actor":"clinic","cost":"large","horizonYears":4},"route":"/ideas/idea-reg-point-of-care-cart-network/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"trial":[{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/"},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/"},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/"},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/"},{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/"},{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/"}],"idea":[{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/"}]}}